Alnylam Issues Inaugural Corporate Responsibility Summary
Alnylam Pharmaceuticals (Nasdaq: ALNY) has published its first Corporate Responsibility (CR) Summary, outlining its environmental, social, and governance (ESG) standards. Key commitments include increasing minority participation in clinical trials, promoting female leadership, and enhancing employee support programs. The report emphasizes Alnylam's dedication to sustainability and accountability, led by a new CR Committee. It marks a significant step toward the company's vision of becoming a top 5 biotech firm while adhering to its core values.
- New Corporate Responsibility (CR) Summary launched, showcasing ESG commitments.
- Commitment to increasing minority participation in clinical trials.
- Initiatives for promoting female leadership and health equity.
- Focus on enhancing employee support programs amid COVID-19.
- None.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today issued its first Corporate Responsibility (CR) Summary, formalizing the management, tracking and communication of its environmental, social and governance (ESG) standards worldwide. The summary highlights Alnylam’s commitments to sustainable business practices and demonstrated focus on its people, the communities it intends to serve, and the planet. The summary, available online at Alnylam.com, features case studies and analyses that illustrate the company's CR-driven philosophy, accomplishments, aspirations and areas of future focus.
“Since its founding, Alnylam has been purpose-driven and socially conscious. Our culture prioritizes people, communities – both patient communities and those in which we have operations - and the planet to stay at the forefront of transformational solutions that improve lives,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “In this new summary we are providing a snapshot of how Alnylam’s core values are a compass for corporate responsibility, how this foundation has enabled us to respond to our world in new ways, and how it will keep us accountable while growing our business towards becoming a top 5 biotech company. This marks an important first step in our ongoing commitment to being a responsible business and to set goals that will measure and propel that progress.”
New Strategic Framework for Corporate Responsibility
Alnylam’s CR theme – Accepting Challenges to Improve the Health of Humanity – describes the Company’s ongoing commitment to tackling unprecedented and complex challenges, taking courageous action, and using its business as a force of good. The Company’s CR efforts are organized into five interconnected, stakeholder-related focus areas: patients, science, employees, communities, and planet.
A guiding imperative, leadership team and set of accountabilities to track and manage Alnylam’s impact are being established for each area. Alnylam has also implemented an enhanced governance structure to support its new CR framework, led by a new cross-functional CR Committee with direction from the Management Board and oversight from Alnylam’s Board of Directors.
Key initial priorities outlined in the CR summary include:
- Increasing participation of minority populations in Alnylam clinical trials;
- Launching new programs focused on female leadership and health equity in the U.S. and other regions;
-
Increasing the overall number of Black and Latinx individuals that make up the Company’s U.S. employee base at all levels by
20% , in coordination with Alnylam’s new Chief Diversity, Equity and Inclusion (DE&I) Officer; - Expanding Alnylam’s existing programs to support employees, including COVID response, workplace safety, and mental health; and
- Sustainability of Alnylam office space and operations, with the implementation of baseline metrics for solid waste worldwide, use of plastics and energy, and greenhouse gas emissions by 2022.
Accepting Challenges to Improve the Health of Humanity builds upon Alnylam’s decade long tradition of creating and meeting ambitious goals. Prior to its CR commitment, Alnylam made a similar commitment with its 2017 Patient Access Philosophy, for which it has annually measured the company’s progress on education, advocacy and assistance, commercial and clinical access.
To read more about Alnylam’s CR summary, framework and key priorities, download Corporate Responsibility at Alnylam here.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam’s expectations, plans, aspirations, goals and priorities, including those related to CR and ESG matters, becoming a top 5 biotech company and the achievement of its “Alnylam P5x25” strategy, as well as Alnylam’s general expectations of meeting ambitious goals constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Novartis, Regeneron and Vir; the outcome of litigation; the risk of government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
This release is not intended to convey conclusions about efficacy or safety as to any investigational RNAi therapeutics or investigational uses previously approved therapeutics. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005309/en/
